ROCKVILLE, Md.--(BUSINESS WIRE)--
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases, today
announced that the Company expects to report fourth quarter and full
year 2013 financial results after the market closes Wednesday, March 12,
2014. CEO, Jack Khattar, and CFO, Greg Patrick, will be hosting a
conference call on Thursday, March 13, 2014 at 9:00 AM Eastern Time, to
discuss 2013 financial results and to provide a business update.
A live webcast will be available at www.supernus.com.
Following the live call, a replay will be available on the Company's
website under 'Investor Info'. The webcast will be archived on the
Company's website for 30 business days following the live call.
Please refer to the information below for conference call dial-in
information. Callers should dial in approximately 10 minutes prior to
the start of the call.
|
|
|
|
|
|
Conference dial-in:
|
|
|
877-288-1043
|
|
International dial-in:
|
|
|
970-315-0267
|
|
Conference ID:
|
|
|
54977145
|
|
Conference Call Name:
|
|
|
Supernus Pharmaceuticals 4Q 2013 Earnings Conference Call
|
|
|
|
|
|
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on developing and commercializing products for the treatment of
central nervous system, or CNS, diseases. The Company has two marketed
products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and
Trokendi XR™ (extended-release topiramate). The Company is also
developing several product candidates in psychiatry to address large
market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive
aggression in ADHD and SPN-812 for ADHD.
Supernus Pharmaceuticals, Inc.
Jack A. Khattar, 301-838-2591
President
and CEO
or
Gregory S. Patrick, 301-838-2591
Vice
President and CFO
or
Investor Contact:
Cockrell Group,
877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Source: Supernus Pharmaceuticals, Inc.
News Provided by Acquire Media